<DOC>
	<DOCNO>NCT03041298</DOCNO>
	<brief_summary>Guerbet conduct non-interventional post-marketing surveillance study Magnetic Resonance Imaging ( MRI ) contrast agent Dotarem ( gadoteric acid/gadoterate meglumine ) September 2011 December 2013 . The aim study , conduct accordance section 67 , paragraph 6 German drug regulation , Arzneimittelgesetz , generate additional data diagnostic efficacy , reliability safety Dotarem Magnetic Resonance ( MR ) mammography .</brief_summary>
	<brief_title>Post Marketing Surveillance Study Evaluation Efficacy Safety Dotarem Magnetic Resonance Mammography</brief_title>
	<detailed_description>Diagnostic efficacy assess basis image quality ( 5-stage scale `` excellent '' `` poor '' ) , diagnosis cytology test result . Safety assess basis frequency seriousness adverse drug reaction observe follow injection Dotarem .</detailed_description>
	<criteria>Patients schedule highresolution MR mammography use MRI contrast agent Dotarem</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>